I don’t know about you, but the relentless drum beat of negative news has been getting to me lately. Every day seems to bring news of some drastic four-figure layoff...er, restructuring, whether in pharma or other industries.
At a meeting at DIA in Boston yesterday, Mike Svinte, President of Global Life Sciences at IBM provided a sneak peek and insights into a new report probing CEO challenges and concerns and their implications. The report, which is due to be released next month, will distill interviews with more...
We all know that physicians must distance themselves from patients to keep from becoming too emotionally involved in each case. Perhaps this applies to drug development and manufacturing as well, and industry profesionals may risk viewing adverse patient reactions as a mere statistic.
Friday will bring a new White Paper, "The Continuing Evolution of the Pharmaceutical Industry: Career Challenges and Opportunities" by Michael Steiner et al, of RegentAtlantic Capital LLC. that tackles a critical topic: job security for the senior-level professional in an industry that's undergoing major transition.
We'd developed an RSS feed of Bloomberg and AP clips pertinent to pharma, but let it slide a bit, due to technical issues and the fact that Bloomberg et al. didn't cover the drug industry (at least on TV) as much as they generally do, in May.
From the corporate governance group, The Corporate Library... CEOS UP $1.26 BILLION, SHAREHOLDERS DOWN $330 BILLION The Corporate Library's latest study of executive incentive compensation practices finds in its five-year analysis that twelve large U.S. companies display the most pronounced gap between pay and performance.